AiNEX (bevacizumab biosimilar) / Mycenax - LARVOL DELTA

Manish Kohli, MD, on Cost Effectiveness of Therapy for Metastatic Renal Cell Cancer - Study looked at top seven first-line options, calculating what gives patients the most quality-adjusted life years (MedPageToday) - "Manish Kohli, MD...explored that question in a study published in JCO Oncology Practice. They estimated the cost and effectiveness of the top seven first-line treatments for mRCC....Kohli elaborated on the findings and implications of the study in the following interview, along with..."

Interview

Effect of trans-arterial embolization on post-ablation hematoma volumes in percutaneous cryoablation of T1b or T2 renal cell carcinoma. (SIO 2023) - "In this study, patients with T1b or T2 RCC treated with TAE prior to CA had no hemorrhagic complications after CA and had smaller volume hematomas; although, the latter did not reach statistical significance, despite having larger and more complex tumors."

Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer (Targeted Oncology) - "Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and carboplatin. Winer says that while studies are currnetly being done regarding bevacizumab's effecacy in breast cancer, those studies may not move forward due to this information."

Video

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer (OncLive) - "'[Approximately] 80% of patients with advanced ovarian cancer [have disease] recurrence,' Bradley J. Monk, MD, said in an interview with OncologyLive....'The underlying thought behind ADCs is compelling....The ADC delivers toxic poisons that we couldn't normally give a patient [directly to the cancer cells],' Robert Wenham, MD, MS, said in an interview with OncologyLive. 'One of the Achilles heels of this program for several years was what links the antibody with the target to the poison itself....linkers better so they release the poison when you want to. That has been what's brought ADCs forward, because there have been a lot smart [individuals] working on this for a very long time, but it is the linker mechanism that has made this viable,' said Wenham,...'We see with mirvetuximab soravtansine for patients [whose disease] overexpresses FRα, that is a good target because it's overexpressed in the vast number of ovarian cancers...."

Media quote

Dr. Monk on Platinum Ineligibility and Emerging ADCs in Ovarian Cancer (OncLive) - "Bradley J. Monk, MD, FACS, FACOG, discusses the role platinum-based chemotherapy in recurrent ovarian cancer, plus emerging antibody-drug conjugates in the space....Since the majority of patients with ovarian cancer eventually recur, determining if they are eligible for platinum-based chemotherapy is vital, even in patients who might have been historically considered to have platinum-resistant recurrent ovarian cancer, Monk says....Although there is not a bevacizumab/PARP inhibitor combination approved in for the treatment of patients who have recurred, bevacizumab can be utilized multiple times, Monk continues. Importantly, it is necessary to be aware of the risk of gastrointestinal perforation with multiple lines of therapy and understand the risk factors, Monk says.All patients who recur becoming platinum ineligible over time and eventually die of their disease, creating the highest unmet medical need in ovarian cancer, Monk explains."

Video

ORIENT-31: Novel Four-Drug Regimen Evaluated in EGFR-Mutated NSCLC (THE ASCO POST) - P3 | N=444 | ORIENT-31 (NCT03802240) | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | " These results from the global phase III ORIENT-31 trial were presented during the 2021 ESMO Virtual Plenary by Shun Lu...The regimen of sintilimab plus IBI305 and chemotherapy reduced the hazard ratio for disease progression by 53.6%, and the curves separated soon after treatment initiation, suggesting early response."

Media quote • P3 data

Episode 11: Novel Combinations Under Study for HCC (Targeted Oncology) - "Richard S. Finn, MD: You touched on a few things. As patients are better compensated, getting started on systemic treatment at the right time, they are going to cycle through many drugs, outside of going on a clinical trial, which is always the best option. In practice, patients will get more drugs based on what we have available. The options probably include I/O [immuno-oncology], or immune checkpoint inhibitor combinations after prior I/O, in reality....Catherine Frenette, MD: One of the places we really need to have the data is when we consider moving these amazing systemic therapies into an earlier-stage patient."

Video

Liver cancer, atezolizumab with bevacizumab improves survival [Google translation] - "'Atezolizumab in combination with bevacizumab, as demonstrated by the data update from the IMbrave150 study, represents an important treatment option for patients living with unresectable hepatocellular carcinoma and provides the longest overall survival observed in a Phase III study first line for this pathology - said Professor Lorenza Rimassa...these are extremely encouraging data as they underline the greater efficacy and tolerability compared to standard therapies, an aspect that could significantly affect the quality of life of patients. This treatment option also opens the way to an approach that increasingly involves the involvement of clinicians with different skills in order to treat patients in a systemic way.'"

Media quote

Episode 7: Atezolizumab/Bevacizumab Data in Frontline HCC (Targeted Oncology) - "Richard S. Finn, MD: In liver cancer, we recently saw the approval of atezolizumab, a PD-L1 antibody, in combination with bevacizumab, an anti-VEGF antibody, based on the IMbrave150 study that was published in the New England Journal of Medicine in May of 2020. The drug was approved by the FDA a few weeks later. For the first time, we have a regimen that improved overall survival [OS] versus sorafenib, right? We had commented that lenvatinib and sorafenib were noninferior. However, we actually saw very significant improvement in overall survival, with a hazard ratio for OS of 0.58; improvement in PFS [progression-free survival], with a hazard ratio of 0.59; and response rates of about 27%-objective response rates....Catherine Frenette, MD: I was actually very impressed with the safety that I saw in the studies. They were very careful about choosing patients."

Video